Research You Can Use

Quantifying the social costs of pharmaceutical opioid misuse and illicit opioid use to Australia in 2015/16

In recent decades the range and patterns of opioids used for extra-medical purposes have changed. The use of pharmaceutical opioids exceeds the use of heroin. In 2017, 63 percent of opioid deaths were attributed exclusively to pharmaceutical opioids, 28 percent to illicit opioids and 8 percent to both illicit and pharmaceutical opioids (aged 15-64 years).

Quantifying the social costs of pharmaceutical opioid misuse and illicit opioid use to Australia in 2015/16 Read More »

Hospitalizations and Deaths Associated with EVALI (Vaping/E-Cigarettes)

As of January 7, 2020, a total of 2558 hospitalized patients with nonfatal cases and 60 patients with fatal cases of e-cigarette, or vaping, product use–associated lung injury (EVALI) had been reported to the Centers for Disease Control and Prevention (CDC). CONCLUSIONS: Chronic conditions, including cardiac and respiratory diseases and mental health conditions, were common among

Hospitalizations and Deaths Associated with EVALI (Vaping/E-Cigarettes) Read More »

Regulating Vaping — Policies, Possibilities, and Perils (NEJM)

Soaring rates of vaping among young people and associated problems have resulted in great urgency and important challenges for policymakers. Despite the urgency, policies should be evidence-based and thoughtfully designed. They require effective, collaborative, and well-funded enforcement by federal and state governments. Policymakers should aim to reduce vaping among young people while maintaining avenues to

Regulating Vaping — Policies, Possibilities, and Perils (NEJM) Read More »

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class

Treating major depressive disorder remains an important challenge worldwide. The disorder impairs productivity, social functioning, and overall health, reducing life expectancy and burdening health care systems.1 Although many treatments exist, at least a third of patients do not have a response after two or more trials of antidepressant drugs and are considered to have treatment-resistant depression.2 Such

Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class Read More »

Scroll to Top